COVID-19 and lymphangioleiomyomatosis: Experience at a reference center and the potential impact of the use of mTOR inhibitors

Am J Med Genet A. 2020 Dec;182(12):3068-3070. doi: 10.1002/ajmg.a.61877. Epub 2020 Sep 18.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • COVID-19*
  • Humans
  • Lymphangioleiomyomatosis*
  • Pandemics
  • TOR Serine-Threonine Kinases

Substances

  • MTOR protein, human
  • TOR Serine-Threonine Kinases